Gsk (GLAXF) Change in Working Capital (2011 - 2022)

Gsk's Change in Working Capital history runs 12 years deep, the most recent figure standing at -$232.2 million for Q4 2022.

• In Q4 2022, Change in Working Capital rose 78.7% year-over-year to -$232.2 million; the TTM figure through Dec 2022 stood at -$2.7 billion (up 12.08% YoY), while the FY2018 annual figure was -$82.8 million, up 32.34% from the prior year.
• Change in Working Capital was -$232.2 million for Q4 2022 at Gsk, down from $1.3 billion in the prior quarter.
• In the past five years, Change in Working Capital ranged from a high of $1.3 billion in Q2 2022 to a low of -$1.7 billion in Q1 2020.
• Historically, Change in Working Capital has averaged -$735.6 million across 5 years, with a median of -$735.4 million in 2018.
• The sharpest annual moves came in 2021 and 2022: Change in Working Capital slumped 73.51% in 2021, then jumped 78.7% in 2022.
• A 5-year view of Change in Working Capital shows it stood at -$1.4 billion in 2018, then gained by 11.91% to -$1.3 billion in 2019, then jumped by 50.62% to -$628.5 million in 2020, then plunged by 73.51% to -$1.1 billion in 2021, then jumped by 78.7% to -$232.2 million in 2022.
• The last three Change in Working Capital figures came in at -$232.2 million (Q4 2022), $1.3 billion (Q2 2022), and -$1.1 billion (Q4 2021), per Business Quant data.